ABBV vs PLTR: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Palantir Technologies Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-16.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
Palantir Technologies Inc. · Technology
$142.76
-24.3% upside to fair value
Med Conviction
Grade C
QuantHub Verdict
ABBV has more upside to fair value
(+4.5%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
PLTR |
| Current Price |
$208.05 |
$142.76 |
| Fair Value Estimate |
$217.50 |
$108.00 |
| Upside to Fair Value |
+4.5%
|
-24.3%
|
| Market Cap |
$367.9B |
$327.1B |
| Forward P/E |
14.9x
|
209.7x
|
| EV / EBITDA |
16.7x
|
—
|
| Price / Sales |
6.1x
|
73.1x
|
| Price / FCF |
20.9x
|
155.7x
|
| Revenue Growth YoY |
+8.6%
|
+19.1%
|
| Gross Margin |
83.7%
|
82.4%
|
| Operating Margin |
34.7%
|
31.6%
|
| Return on Equity |
-129.24%
|
25.7%
|
| Dividend Yield |
3.2% |
— |
| FCF Yield |
4.78%
|
0.6%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
Palantir Technologies develops data analytics and AI software platforms like Gotham and Foundry for government and commercial clients. The business excels with high margins (gross 82.4%, net 36.3%), accelerating growth (Q4 FY2025 revenue up 70% YoY to $1.41B, 2026 guidance $7.19B implying 61% growth), and strong moats in defense and enterprise AI, but trades expensively at 73x P/S versus 5-year m…
Accumulation Zones
| Metric |
ABBV |
PLTR |
| Zone Low |
$163.13 |
$81.00 |
| Zone High |
$184.88 |
$92.00 |
| In Buy Zone? |
No
|
No
|